INS and pancreatitis: A systematic review and meta-analysis of 9 RCT showed that the administration of TZP was associated with a similar risk of pancreatitis compared to basal insulin or placebo or selected GLP-1RA, while the risk of composite gallbladder or biliary diseases vs. basal insulin or placebo was found to be increased [6].